Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans

被引:108
|
作者
Schmajuk, Gabriela [1 ]
Trivedi, Amal N. [2 ]
Solomon, Daniel H. [3 ]
Yelin, Edward [4 ]
Trupin, Laura [4 ]
Chakravarty, Eliza F. [1 ]
Yazdany, Jinoos [4 ]
机构
[1] Stanford Univ, Dept Med, Div Rheumatol, Stanford, CA 94304 USA
[2] Brown Univ, Dept Community Hlth & Med, Providence, RI 02912 USA
[3] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02115 USA
[4] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA USA
来源
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
QUALITY-OF-CARE; HEALTH PLANS; DISPARITIES; OUTCOMES; DATABASE; COST; BENEFICIARIES; NEIGHBORHOOD; MEDICATIONS; AMERICAN;
D O I
10.1001/jama.2011.67
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context In 2005, the Healthcare Effectiveness Data and Information Set (HEDIS) introduced a quality measure to assess the receipt of disease-modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA). Objective To identify sociodemographic, community, and health plan factors associated with DMARD receipt among Medicare managed care enrollees. Design, Setting, and Participants We analyzed individual-level HEDIS data for 93 143 patients who were at least 65 years old with at least 2 diagnoses of RA within a measurement year (during 2005-2008). Logistic regression models with generalized estimating equations were used to determine factors associated with DMARD receipt and logistic regression was used to adjust health plan performance for case mix. Main Outcome Measures Receipt or nonreceipt of DMARD. Results The mean age of patients was 74 years; 75% were women and 82% were white. Overall performance on the HEDIS measure for RA was 59% in 2005, increasing to 67% in 2008 (P for trend <.001). The largest difference in performance was based on age: patients aged 85 years and older had a 30 percentage point lower rate of DMARD receipt (95% confidence interval [CI], -29 to -32 points; P<.001), compared with patients 65 to 69 years of age, even after adjusting for other factors. Lower percentage point rates were also found for patients who were men (-3 points; 95% CI, -5 to -2 points; P<.001), of black race (-4 points; 95% CI, -6 to -2 points; P<.001), with low personal income (-6 points; 95% CI, -8 to -5 points; P<.001), with the lowest zip code-based socioeconomic status (-4 points; 95% CI, -6 to 2 points; P<.001), or enrolled in for-profit health plans (-4 points; 95% CI, -7 to 0 points; P<.001); and in the Middle Atlantic region (-7 points; 95% CI, -13 to -2 points; P<.001) and South Atlantic regions (-11 points; 95% CI, -20 to -3 points; P<.001) as compared with the Pacific region. Performance varied widely by health plan, ranging from 16% to 87%. Conclusions Among Medicare managed care enrollees carrying a diagnosis of RA between 2005 and 2008, 63% received a DMARD. Receipt of DMARDs varied based on demographic factors, socioeconomic status, geographic location, and health plan. JAMA. 2011;305(5):480-486 www.jama.com
引用
收藏
页码:480 / 486
页数:7
相关论文
共 50 条
  • [1] PATIENT, HEALTH PLAN AND COMMUNITY FACTORS ASSOCIATED WITH RECEIPT OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN MEDICARE MANAGED CARE PLANS
    Mehta, S.
    Teigland, C.
    Pulungan, Z.
    Kilgore, K.
    Parente, A.
    McClellan, M.
    Jones, B.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A166 - A167
  • [2] Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries
    Yazdany, Jinoos
    Tonner, Chris
    Schmajuk, Gabriela
    [J]. ARTHRITIS CARE & RESEARCH, 2015, 67 (09) : 1210 - 1218
  • [3] Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Rosales Rosado, Zulema
    Leon, Leticia
    Freites Nunez, Dalifer
    Font Urgelles, Judit
    Leon Cardenas, Cynthia Milagros
    Vadillo Font, Cristina
    Rodriguez Rodriguez, Luis
    Jover Jover, Juan A.
    Abasolo Alcazar, Lydia
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Mittal, Niti
    Mittal, Rakesh
    Sharma, Aman
    Jose, Vinu
    Wanchu, Ajay
    Singh, Surjit
    [J]. SINGAPORE MEDICAL JOURNAL, 2012, 53 (08) : 532 - 536
  • [5] Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs
    Kay, Jonathan
    Rancourt, Joshua
    Bradley, John D.
    Arora, Vipin K.
    Zhong, Jinglin
    Dickson, Christina
    Muram, David
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [6] Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis
    Di Munno, O
    Delle Sedie, A
    Rossini, A
    Adamil, S
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (02) : 137 - 144
  • [7] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    [J]. DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [8] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
    Martinez-Mugica, Cristina
    Salgueiro, Esther
    [J]. FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
  • [10] The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Otani, Hiroshi
    Abe, Asami
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    [J]. INTERNAL MEDICINE, 2023, 62 (03) : 373 - 379